Clinical answers, traced to the source.

Question: ozempic Glp1 and oral birth control

both
Semaglutide, a GLP-1 receptor agonist marketed as Ozempic, does not significantly affect the bioavailability of oral contraceptives containing ethinylestradiol and levonorgestrel. A study demonstrated that semaglutide did not reduce the bioavailability of these contraceptive components, meeting bioequivalence criteria for ethinylestradiol and showing a 20% increase in levonorgestrel exposure, which is not considered clinically significant 8. However, due to semaglutide's effect on delaying gastric emptying, there is a theoretical concern that it might affect the absorption of oral medications, including contraceptives, although this has not been shown to be clinically significant in studies 67. Supporting detail: The pharmacokinetic interaction study with semaglutide showed that the area under the curve (AUC) for ethinylestradiol remained within the bioequivalence range, while the AUC for levonorgestrel was slightly increased, indicating no reduction in contraceptive efficacy 8. Despite the potential for delayed gastric emptying to impact drug absorption, the clinical significance of this effect on oral contraceptives is minimal 67. Key evidence: The cited literature and FDA labeling confirm that semaglutide does not significantly alter the pharmacokinetics of oral contraceptives 678.

References

  1. 8

    Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.

    LiteratureJ Clin Pharmacol · 2015

    https://pubmed.ncbi.nlm.nih.gov/25475122/
  2. 6

    Semaglutide — FDA Prescribing Information (Drug Interactions)

    FDA labelOfficial labeling · 2026

    https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  3. 7

    A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

    LiteratureDrug Des Devel Ther · 2025

    https://pubmed.ncbi.nlm.nih.gov/40330819/

Educational reference only. Not medical advice, diagnosis, or treatment. Verify with primary sources and use professional clinical judgment.

← Browse more questions